Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 20-1438
More information available at ClinicalTrials.gov: NCT04197986
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers